Broken up by sectors, Pfizer earned $10.5 billion with vaccines, $9.7 billion with hospital, $3.1 billion with oncology and $2.4 billion with internal medicine. Its manufacturing side, Pfizer CentreOne, brought in $317 million.
Three more things to know, according to the report:
1. So far this year, the pharmaceutical company earned $53.4 billion in revenue, and half of that number is because of its vaccine research, development and manufacturing side. The report shows a 47 percent increase in second-quarter revenue compared to 2021’s second quarter.
2. Pfizer anticipates its COVID-19 vaccine will bring in $32 billion in revenue in fiscal year 2022 and that its antiviral, at-home treatment Paxlovid will bring in $22 billion.
3. Recent developments during the second quarter include the FDA and CDC’s authorization of Pfizer’s COVID-19 vaccine for children between 6 months and 5 years old and its work to test an updated vaccine against omicron’s dominating subvariants.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
